Felix Health Cuts Semaglutide Prices as Demand for Virtual Weight Loss Soars

New updates have been reported about Felix Health.

Felix Health Inc., Canada’s largest virtual weight loss clinic, is cutting prices on semaglutide treatments by up to 65% as generic GLP-1 options gain approval and supply improves, with changes potentially effective as early as May 29. The move directly targets cost as a key barrier to treatment, after internal data showed nearly one in four weight management patients who stopped their Felix program in the past year cited price as the primary reason.

The company has seen weight loss subscribers climb 99% year over year, and weight management now accounts for nearly 30% of more than 1.1 million clinical consultations delivered on its platform, underscoring the strategic importance of this category for Felix’s growth. With Canada the first G7 market to approve generic semaglutide and Health Canada reviewing additional submissions, Felix expects GLP-1 prices to decline further, which could reduce annual out-of-pocket costs by thousands of dollars for uninsured patients and broaden its addressable market among Canadians with type 2 diabetes and those eligible for chronic weight management therapy.

Despite strong demand, affordability remains a structural challenge: less than 5% of Felix weight management patients are fully covered by insurance, and among those without savings plans, 86% pay entirely out of pocket. Survey data commissioned by Felix from Angus Reid in December 2025 found that 28% of Canadians living with overweight or obesity would consider a GLP-1 at $100 per month, but only 5% would at $400, highlighting the elasticity of demand and the potential upside from lower pricing.

Chief Pharmacy Officer Tracey Phillips emphasized that price is only part of the care equation, noting that long-term outcomes depend on ongoing screening, dose titration, side-effect management, and follow-up support that Felix delivers through its virtual model. Co-Founder and CEO Kyle Zien framed the price reductions as both an access initiative and a strategic response to a maturing GLP-1 market, stating that lower-cost generics, combined with medically supervised virtual care, can shift GLP-1 treatment from a niche option to a scalable solution for millions of Canadians.

For Felix, the decision to reset semaglutide pricing is likely to compress per-patient revenue in the short term but could drive higher patient volumes, longer treatment duration, and stronger retention in a rapidly expanding category. The move also positions the company competitively as payers, regulators, and patients increasingly scrutinize the value and affordability of GLP-1 therapies, while reinforcing Felix’s broader digital health strategy, which spans menopause, sexual health, dermatology, and hair loss to diversify revenue beyond weight loss.

Founded in 2019, Felix has built a national footprint in digital healthcare and is currently trusted by more than 1.5 million Canadians for online assessments, treatment plans, prescription delivery, and longitudinal care. As generic GLP-1 availability increases and pricing pressure intensifies, Felix’s ability to combine lower drug costs with integrated virtual support will be central to sustaining growth, defending market share in weight management, and potentially attracting new partnerships or capital to scale its platform.